Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

The Fragile X syndrome protein as RNA distribution hub

06.02.2003


New technique tracks RNAs associated with the protein responsible for Fragile X



The process of turning genes into protein makes the insides of cells terribly crowded and complicated places. Signals tell machinery to transcribe the DNA of genes into messenger RNA (mRNA) whose translation into protein has to be coordinated with everything else that is happening within the cell. Fortunately, there are RNA binding proteins to organize mRNAs. These proteins are so critical that the loss of one particular RNA binding protein, FMRP, leads to Fragile X syndrome, the most common inherited forms of mental retardation.

Researchers based at the University of Pennsylvania School of Medicine invented a technique called Antibody Positioned RNA Amplification (APRA) to determine the identity of RNA molecules associated with RNA binding proteins. Their findings on FMRP, presented in the February 6th issue of the journal Neuron, further define the complex basis of Fragile X syndrome.


Fragile X syndrome is the most common inherited cause of mental retardation in both men and women. The disorder causes mental abnormalities that range from slight learning disabilities to severe mental retardation. The syndrome is caused by a mutation in what has been termed the Fragile X mental retardation-1 (Fmr1) gene, which encodes FMRP, the Fragile X mental retardation protein.

"RNA-binding proteins regulate all aspects of RNA synthesis, such as mRNA transcription, splicing and editing, as well as translation of mRNA into protein," said James Eberwine, PhD, professor in Penn’s Department of Pharmacology. "The mRNAs held by FMRP encode for proteins that assist in transmitting signals within the brain. FMRP provides cellular mRNA traffic control, and moves selected mRNAs to sites where they can be translated. How FMRP knows where to move these mRNAs and how these mRNAs are released from FMRP is unclear at present."

To study how RNA binding proteins such as FMRP function, Eberwine and his colleagues developed a technique to identify specific mRNAs associated with a particular binding protein. At its basis, APRA enables researchers to analyze an RNA binding protein’s cargo on a genome-wide basis.

In practice, APRA works a bit like a homing beacon attached to a photocopier: Eberwine connected an antibody that specifically binds to FMRP to a DNA molecule that can bind to the RNA near the FMRP protein. In the presence of enzymes, the DNA molecule helps copy these RNAs into cDNA (a term for DNA made from RNA).

After it is synthesized, the cDNA is amplified into hundreds of thousands of RNA molecules by an amplification procedure also developed in the Eberwine lab a few years ago. These amplified RNA molecules can be screened against a microarray to identify their corresponding genes. In this bridging of genomics (the study of the genome) and proteomics (global analysis of proteins), the specificity of the antibody’s attraction to FMRP induces the specificity of the RNA analysis. Given the nature of Fragile X syndrome – and the fact that FMRP is found only in the tissues of the central nervous system – the researchers were encouraged to find that among the FMRP’s cargo are mRNAs encoding proteins involved in transmitting signals between neurons and in neuron maturation.

As a research tool, the researchers believe that APRA analysis has great potential for researchers who want to target specific RNA binding proteins for analysis. Given its specificity, ARPA can track down RNA binding proteins that are only found in certain tissues and examine those proteins under varying physiological conditions or disease states.

"In that sense, APRA could mean to RNA studies as much as DNA and RNA amplification techniques have meant to studying the genome," said Eberwine. "It is also part of the growing frontier of molecular biology – somewhere between genomics and proteomics is the interplay of RNA with RNA-binding proteins."

Researchers also involved in these findings include: lead author Kevin Miyashiro of Penn’s Department of Pharmacology; Andrea Beckel-Mitchener, T. Patrick Purk, Ivan Jeanne Wieler, Willam T. Greenough, of the Beckman Institute at the University of Illinois; Lei Liu of the W.M. Keck Center for Comparative and Functional Genomics at the University of Illinois; Salvatore Carbonetto of the Centre for Neuroscience Research at McGill University; and Kevin G. Becker and Tanya Barret of the DNA Array Unit of the National Institute on Aging.


###
This research was funded through grants from the National Institute on Aging and the National Institute of Mental Health.

Greg Lester | EurekAlert!
Further information:
http://www.med.upenn.edu/

More articles from Life Sciences:

nachricht Biophysicists reveal how optogenetic tool works
29.05.2020 | Moscow Institute of Physics and Technology

nachricht Mapping immune cells in brain tumors
29.05.2020 | University of Zurich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Biotechnology: Triggered by light, a novel way to switch on an enzyme

In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".

Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...

Im Focus: New double-contrast technique picks up small tumors on MRI

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.

researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...

Im Focus: I-call - When microimplants communicate with each other / Innovation driver digitization - "Smart Health“

Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.

When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

Black nitrogen: Bayreuth researchers discover new high-pressure material and solve a puzzle of the periodic table

29.05.2020 | Materials Sciences

Argonne researchers create active material out of microscopic spinning particles

29.05.2020 | Materials Sciences

Smart windows that self-illuminate on rainy days

29.05.2020 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>